SAN DIEGO — Qureator is pleased to announce the appointment of Paul Park as its new consulting Chief Business Officer (CBO).
Paul is a seasoned biotechnology executive with over two decades of experience in strategy, partnerships, M&A, and financing across leading biopharma and healthcare technology companies.
Throughout his career at Amgen, Ionis Pharmaceuticals, and Circle Pharma, Paul has helped shape multi-billion-dollar pipelines and execute high-impact transactions across co-development/co-commercialization partnerships, licensing, acquisitions, research collaborations, and venture financing. His experience spans the full business lifecycle — from platform validation to global commercialization — and includes overseeing more than 30 alliances with several of the world’s top pharmaceutical companies.
Paul joins Qureator at a pivotal moment following our FDA-validated, animal-POC-free IND success and the increasing adoption of our vascularized, immune-competent human disease models. As demand grows for human-relevant data to guide target selection, responder prediction, and clinical translation beyond IND-enabling decisions, Paul’s leadership will help Qureator deepen strategic partnerships, expand globally, and strengthen our position as the category-defining AI-powered human biology platform for next-generation drug discovery and development.